490 related articles for article (PubMed ID: 23325831)
1. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
3. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
[TBL] [Abstract][Full Text] [Related]
5. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
Pien GC; Basner-Tschakarjan E; Hui DJ; Mentlik AN; Finn JD; Hasbrouck NC; Zhou S; Murphy SL; Maus MV; Mingozzi F; Orange JS; High KA
J Clin Invest; 2009 Jun; 119(6):1688-95. PubMed ID: 19436115
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
9. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
12. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
13. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes.
Hui DJ; Basner-Tschakarjan E; Chen Y; Davidson RJ; Buchlis G; Yazicioglu M; Pien GC; Finn JD; Haurigot V; Tai A; Scott DW; Cousens LP; Zhou S; De Groot AS; Mingozzi F
Mol Ther; 2013 Sep; 21(9):1727-37. PubMed ID: 23857231
[TBL] [Abstract][Full Text] [Related]
14. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
Lisowski L; Dane AP; Chu K; Zhang Y; Cunningham SC; Wilson EM; Nygaard S; Grompe M; Alexander IE; Kay MA
Nature; 2014 Feb; 506(7488):382-6. PubMed ID: 24390344
[TBL] [Abstract][Full Text] [Related]
15. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.
Li H; Tuyishime S; Wu TL; Giles-Davis W; Zhou D; Xiao W; High KA; Ertl HC
Mol Ther; 2011 Mar; 19(3):536-46. PubMed ID: 21157435
[TBL] [Abstract][Full Text] [Related]
18. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.
Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478
[TBL] [Abstract][Full Text] [Related]
19. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
20. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
Front Immunol; 2018; 9():844. PubMed ID: 29725339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
